Promising lung cancer combo study pulled before starting
NCT ID NCT06732258
First seen May 01, 2026 · Last updated May 10, 2026 · Updated 1 time
Summary
This study was designed to test the safety and tolerability of a new treatment combination for people with extensive-stage small cell lung cancer who had not received prior treatment. The approach combined low-dose radiation with standard chemotherapy and two immunotherapy drugs (toripalimab and tifcemalimab). However, the study was withdrawn before enrolling any participants, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.